About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Ovarian Cancer Clinical Trials in Tennessee | 383 Studies

Clinical Trials Ovarian CancerTennessee

Ovarian Cancer Clinical Trials in Tennessee

Find 383 clinical trials for ovarian cancer near Tennessee. Connect with research centers in your area.

All Ovarian Cancer trials nationwide All trials in Tennessee

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 361-380 of 383 trials

RecruitingA Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations.NCT06760819·Birmingham, Alabama and 53 others

Ovarian Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

TerminatedA Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid TumorsThis is a Phase 1b/2, open-label, multicenter study of DSP-7888 Dosing Emulsion in combination with checkpoint inhibitors (nivolumab or pembrolizumab) in adult patients with solid…NCT03311334·Tucson, Arizona and 18 others

RecruitingTesting Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian CancerThis phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination…NCT06580314·Birmingham, Alabama and 694 others

TerminatedSC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial CancersThis is a two-part study consisting of Part A (dose regimen finding) followed by Part B (dose expansion).NCT03138408·Birmingham, Alabama and 11 others

Terminated(VELA) Study of BLU-222 in Advanced Solid TumorsThis is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of…NCT05252416·Little Rock, Arkansas and 22 others

SuspendedA Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid TumorThis is an open-label, Phase 1b/2 study to determine the recommended dose of lucitanib in combination with nivolumab in patients with an advanced solid tumor (Phase 1b); followed…NCT04042116·Los Angeles, California and 26 others

Active not recruitingA Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian CancerOvarian cancer is a heterogeneous disease, characterized by complex molecular and genetic changes.NCT03602859·Anchorage, Alaska and 181 others

UnknownDose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid TumorsThe purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of escalating doses of RMC-4630 monotherapy in adult…NCT03634982·Scottsdale, Arizona and 11 others

CompletedA Study of MGD013 in Patients With Unresectable or Metastatic NeoplasmsThe primary goal of this Phase 1 study is to characterize the safety and tolerability of tebotelimab and establish the maximum tolerated dose (MTD) of tebotelimab in advanced…NCT03219268·Gilbert, Arizona and 39 others

CompletedS0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian CancerRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.NCT00043082·Mobile, Alabama and 90 others

CompletedStudy of DF6215 in Patients With Advanced Solid TumorsA Phase I/Ib, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 Monotherapy and in…NCT06108479·Los Angeles, California and 20 others

RecruitingA Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid TumorsThis phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other…NCT06234423·Denver, Colorado and 14 others

Active not recruitingADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)This study will investigate the safety and tolerability of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and MAGE-A4 tumor antigen.NCT04044859·Orlando, Florida and 16 others

CompletedPhase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian CancerThis is a Phase 1 first in human, open label, multi-center, dose escalation study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of…NCT04406623·Duarte, California and 5 others

Active not recruitingNivolumab and Ipilimumab in Treating Patients With Rare TumorsThis phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors.NCT02834013·Birmingham, Alabama and 1006 others

TerminatedA Study of PHN-010 in Patients With Advanced Solid TumorsThis first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-010, a novel antibody-drug…NCT06457997·Orlando, Florida and 7 others

CompletedPhase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic MalignanciesThe purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or…NCT03126110·Los Angeles, California and 37 others

TerminatedPRO1107 in Patients With Advanced Solid TumorsThis is a global, open-label, multicenter Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of GEN1107 (PRO1107) in participants…NCT06171789·Scottsdale, Arizona and 6 others

CompletedA Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian CancerThis is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study of niraparib as maintenance in platinum sensitive ovarian cancer patients who have either…NCT01847274·Phoenix, Arizona and 111 others

TerminatedA Study of NM21-1480 in Adult Patients With Advanced Solid TumorsThis is a first-in-human, open-label, multi-center, Phase 1/2, dose-escalation study with expansion cohorts to evaluate NM21-1480 for safety and immunogenicity, to determine the…NCT04442126·Fort Collins, Colorado and 25 others

PreviousPage 19 of 20Next

Other Conditions in Tennessee

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia